Discover the groundbreaking research combining DNase I with CAR T-cell therapy to enhance cancer treatment efficacy, suppress ...

Innate Pharma's cancer programs, including partnerships with big pharma, show promise. Find out why IPHA stock could offer ...

High cumulative doses of epipodophyllotoxins were associated with the highest risk for survivors of childhood cancer of ...

Yescarta – a CD19-directed genetically modified autologous T-cell ... non-Hodgkin lymphoma are diagnosed each year: roughly 5,500 of those are DLBCL and 330 are PMBCL. Overall survival rate ...

In a recent study published in Nature Cancer, researchers explore treatment resistance and relapse in T-cell acute ...

Researchers have found an increased frequency of severe maternal morbidity and obstetric complications among women who ...

Findings of a recent study indicate that NUP98 rearrangements can significantly impact outcomes in patients with acute myeloid leukemia (AML).

Overall response rate ... targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth quarter of 2024 MB-106 data in B-cell non-Hodgkin lymphoma (NHL ...

Discover which therapies are expected to grab the PD/L-1 Market Share @ PD/L-1 Treatment Market Size ...

Glioblastomas are almost always lethal with a median survival time of 14 ... associated proteins -- rather than one -- with CAR T cell therapy shows promise as a strategy for reducing solid ...

For people 55 and over, AT&T offers unlimited talk, text, and data plans for $40 per month per line; however, only Florida residents are eligible for these plans. For those who don’t live in Florida, ...